Navigation Links
Bayer and Onyx Launch Educational Program to Raise Awareness About Liver Cancer and Its Risk Factors
Date:10/28/2008

tium of doctors from the American Association for the Study of Liver Disease (AASLD).

Since 1979, the Research Awards Program has provided more than US$21 million for research. More than 650 qualified scientists and physicians have pursued careers in liver disease research and treatment as a result of receiving the ALF and AASLD grants early in their careers.

No other voluntary organization in the nation provides a voice for the 30 million Americans with liver disease. The ALF makes a measurable difference in the fight against liver disease by providing financial support for medical research, education for patients and health care professionals, and advocacy and information for patients and their families, and by creating public awareness initiatives about liver wellness and disease prevention.

No matter how you become involved your support of the ALF will make an impact on the 30 million people living with liver disease. Make the commitment to help in your own way today.

To learn more about The American Liver Foundation, Hepatitis and the over 100 other liver diseases, visit us at: http://www.liverfoundation.org.

About Vital Options International

Vital Options International is a not-for-profit cancer communications organization with a mission to facilitate a global cancer dialogue. Founded in 1983, Vital Options was the first organization for young adults with cancer, before expanding to include people of all ages and cancer types with its innovative programs such as The Group Room(R), a weekly cancer talk radio show.

Using creative multimedia technology, Vital Options enables patients and their loved ones to interact and speak directly with noted oncology medical professionals and researchers in the US and Europe, while supporting the efforts of the advocacy community.

Vital Options is headquartered in Southern California, with a European division bas
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Bayer Diabetes Care Partners with Nick Jonas to Encourage Young People to Proactively Manage Their Diabetes
2. Photos: Bayer Names New U.S. CEO
3. Bayer USA Foundation Supports Summer Science Education Programs in Pittsburgh, Raleigh, Houston and Tyler, Texas
4. Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Contraceptives
5. Statement From Bayer(R) Aspirin Regarding the American Medical Associations New Aspirin Policy Resolution
6. Bayer Announces Availability of Reformulated Liquid Leukine(R)
7. ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
8. United Nations Environment Programme and Bayer Corporation Announce North American Winners of International Childrens Painting Competition
9. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
10. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
11. Bayer to Receive Two Top National Awards for Its Science Education, Science Literacy Work
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4CVS Caremark Names New Chief Human Resources Officer 2Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 1Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 2Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 1Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 1NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 5
Other Medicine Technology:Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7